PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers
- PMID: 2747341
PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers
Abstract
Platelet aggregation induced ex vivo by aggregating factors such as adrenaline, ADP, collagen or PAF may be useful as a model for describing drug effects in humans. In the two studies reported here, PAF-induced platelet aggregation ex vivo was used as an indicator of the pharmacological activity in healthy volunteers of the newly developed specific PAF-antagonist WEB 2086. In intravenous and inhalative single rising dose tolerance trials this method proved useful for monitoring the pharmacological action of the compound tested. After administration of placebo no relevant pharmacological activity was observed. In both studies increasing dosages of the test substance showed clear, dose-related inhibition of PAF-induced platelet aggregation. Ex vivo PAF-induced platelet aggregation thus provides a simple and rapid means of assessing functional PAF antagonism during trials of PAF-antagonists in human volunteers.
Similar articles
-
Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.J Pharmacol Exp Ther. 1991 Oct;259(1):78-85. J Pharmacol Exp Ther. 1991. PMID: 1656030
-
Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.Arzneimittelforschung. 1990 Nov;40(11):1201-5. Arzneimittelforschung. 1990. PMID: 2085331
-
Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.Arzneimittelforschung. 1991 Jan;41(1):51-9. Arzneimittelforschung. 1991. PMID: 1646613 Clinical Trial.
-
[Ocular immunopathological characteristics and the involvement of the platelet-aggregation factor and the anti-PAF at the level of the eye].Rev Med Chir Soc Med Nat Iasi. 1999 Jan-Jun;103(1-2):72-6. Rev Med Chir Soc Med Nat Iasi. 1999. PMID: 10756889 Review. Romanian.
-
[Stroke, platelet activating factor and receptor antagonists].Zhongguo Zhong Yao Za Zhi. 2017 Dec;42(24):4750-4755. doi: 10.19540/j.cnki.cjcmm.2017.0212. Zhongguo Zhong Yao Za Zhi. 2017. PMID: 29493142 Review. Chinese.
Cited by
-
Clinical experience with platelet-activating factor antagonists. Past, present, and near future.Clin Rev Allergy. 1994 Winter;12(4):397-417. doi: 10.1007/BF02802302. Clin Rev Allergy. 1994. PMID: 7743464 Review. No abstract available.
-
Inhibition of ex-vivo PAF-induced platelet aggregation by the PAF-antagonist RP 48740: relationship to plasma concentrations in healthy volunteers.Eur J Clin Pharmacol. 1991;41(2):141-5. doi: 10.1007/BF00265907. Eur J Clin Pharmacol. 1991. PMID: 1743246
-
PAF. A review of its effects, antagonists and possible future clinical implications (Part II).Drugs. 1991 Aug;42(2):174-204. doi: 10.2165/00003495-199142020-00002. Drugs. 1991. PMID: 1717219 Review. No abstract available.
-
Thieno-triazolo-1,4-diazepines as antagonists of platelet-activating factor: present status.Lipids. 1991 Dec;26(12):1157-61. doi: 10.1007/BF02536522. Lipids. 1991. PMID: 1668111 Review.